drugset / Trial / NCT04013477
Single-ascending Dose Phase 1 Clinical Trial to Evaluate the Safety and PK of DA-5207 TDS in Healthy Adults
Non-randomizedParallel-groupSingle-blindTreatment
Summary
A single-blinded, placebo- and active-controlled, parallel, single-ascending dose phase 1 clinical trial to evaluate the safety and pharmacokinetics of DA-5207 transdermal delivery system in healthy adults
Timeline
- Start
- 2019-06-18
- Primary completion
- 2019-12-05
- Completion
- 2020-04-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DA-5207 | Unknown | 80 mg | Other |
| Subject | DA-5207 | Unknown | 120 mg | Other |
| Subject | DA-5207 | Unknown | 160 mg | Other |
| Comparator | Donepezil | Small molecule | 10 mg | — |
Indications
No indication recorded.